Cyclophosphamide 1,440 mg IV Preparation in 0.9% Sodium Chloride
Preparation Instructions
To prepare cyclophosphamide 1,440 mg in 257.2 mL of 0.9% sodium chloride, reconstitute the appropriate vials of cyclophosphamide powder with sterile water for injection, then add the reconstituted solution to a bag of 0.9% sodium chloride to achieve the final volume of 257.2 mL.
Step-by-Step Preparation Protocol
Reconstitution of Cyclophosphamide Vials
- Determine vial requirements: For a 1,440 mg dose, you will need to use multiple vials (typically 500 mg, 1 g, or 2 g vials depending on availability) 1
- Reconstitute each vial with sterile water for injection according to manufacturer specifications to create a 20 mg/mL solution 1
- Dissolution time: If using freeze-dried formulation, dissolution occurs within 20 seconds; dry-filled formulations require at least 3 minutes 1
Dilution in 0.9% Sodium Chloride
- Calculate diluent volume: To achieve a final volume of 257.2 mL containing 1,440 mg cyclophosphamide, subtract the volume of reconstituted cyclophosphamide from 257.2 mL to determine how much 0.9% sodium chloride to use 1
- Add reconstituted cyclophosphamide to an appropriate volume of 0.9% sodium chloride for injection to reach the final volume of 257.2 mL 2, 1
- Mix thoroughly by gentle inversion
Stability and Storage Considerations
Chemical Stability Parameters
- Optimal storage: Cyclophosphamide solutions in 0.9% sodium chloride at 1-20 mg/mL concentrations are stable for 7 days at 4°C in the dark 1
- Room temperature stability: At 20-22°C, expect 10% degradation after 7 days 1
- Avoid elevated temperatures: At 37°C, 50% loss occurs after 7 days 1
Container Compatibility
- Both glass and PVC containers are acceptable for cyclophosphamide solutions without significant differences in chemical stability 1
- Light protection: Store in the dark when possible to maximize stability 1
Administration Considerations
Infusion Guidelines
- Infusion rate: The specific infusion rate should be determined based on the clinical indication and institutional protocols 3, 4, 3
- Bladder protection: Consider concurrent administration of mesna to reduce risk of hemorrhagic cystitis, particularly with higher doses 5
- Hydration: Maintain adequate hydration with forced diuresis and frequent bladder emptying to minimize urinary toxicity 5
Monitoring Requirements
- Urinary sediment: Check regularly for erythrocytes and signs of bladder toxicity 5
- Neutropenia monitoring: Monthly monitoring is typically sufficient for IV cyclophosphamide (versus weekly for oral formulations) 3
- Infection surveillance: Patients receiving cyclophosphamide require careful monitoring for infectious complications 5
Critical Safety Considerations
Extravasation Prevention
- Ensure secure IV access before administration, as cyclophosphamide can cause severe skin injury if extravasation occurs 4
- Central line preferred for larger volumes or repeated dosing